TMCnet News
Vedanta Biosciences Announces Clinical Translational Medicine Collaborations with Stanford University School of Medicine and Leiden University Medical Center Focused on Food Allergies and C. difficile and Graft versus Host DiseaseVedanta Biosciences, pioneering the development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, today announced that it has entered into translational medicine collaborations with Stanford University School of Medicine and Leiden University Medical Center. The relationships will focus on food allergies in children and on patients with C. difficile infection or graft-versus-host disease, respectively. Both collaborations seek to better understand patterns in the microbiome that may potentially inform clinical responses to therapy. Under the terms of the agreement with Stanford, Vedanta will work in collaboration with Kari Nadeau, MD, PhD, Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, to analyze the potential connection between the gut microbiome and responses to oral immunotherapies in children with food allergies. With Leiden University, Vedanta will generate clinical data from interventional studies of fecal transplantation in C. difficile patients treated with donors from the Netherlands Donor Feces Bank, as well as clinical data from patients with graft-versus-host disease, in collaboration with Ed Kuijper, MD, PhD, Professor of Medical Microbiology at the Leiden University Medical Center and co-chair of the Netherlands Donor Feces Bank. The clinical data will feed into Vedanta's leading platform for discovery, development, and GMP manufacturing of rationally designed bacterial consortia drugs. "We're excited to announce our relationships with Stanford and Leiden University," said Bruce Roberts, PhD, Chief Scientific Officer of Vedanta Biosciences. "Collaborations with leading academic centers are an important part of our strategy to support our drug development efforts with human data and with careful science."
About Vedanta Biosciences Vedanta Biosciences' scientific co-founders have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale), Dr. Alexander Rudensky (tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University and Cornell University), Dr. Dan Littman (Professor of Molecular Immunology at NYU), Dr. Brett Finlay (Professor at the University of British Columbia) and Dr. Kenya Honda (News - Alert) (Professor, School of Medicine, Keio University). Vedanta is backed by PureTech Health, Seventure, Invesco Asset Management, and Rock Springs Capital.
Forward Looking Statement
View source version on businesswire.com: http://www.businesswire.com/news/home/20170215006392/en/ |